<?xml version="1.0" encoding="UTF-8" standalone="yes"?>
<References xsi:schemaLocation="http://www.iedb.org/schema/CurationSchema http://beta.iedb.org/schema/Curation.xsd" xmlns="http://www.iedb.org/schema/CurationSchema" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <Reference>
        <ReferenceId>910</ReferenceId>
        <DateLastUpdated>2020-09-10-07:00</DateLastUpdated>
        <Article>
            <PubmedId>10733926</PubmedId>
            <Abstract>The synthetic peptide comprising the 317-341 region of human influenza A virus (H1N1 subtype) hemagglutinin elicits peptide-specific antibody and helper T cell responses and confers protection against lethal virus infection. Molecular mapping of the 317-329 region, which encompasses the epitope recognized by peptide-specific T cells, revealed that the minimal size required for T cell activation was the 317-326 segment. The most likely peptide alignment, which placed 320Leu to pocket 1 of the I-E(d) peptide binding groove, was predicted by molecular mechanics calculations performed with the parental and with the Ala-substituted analogs. In line with the prediction data, the results of the peptide binding assay, where the relative binding efficiency to I-E(d) molecules expressed on the surface of antigen-presenting cells was monitored, identified the 320-326 core sequence interacting with the major histocompatibility class II peptide binding groove. Functional analysis of Ala-substituted variants by functional assays and by calculating the surface-accessible areas of the single peptidic amino acids in the I-E(d)-peptide complexes demonstrated that 324Pro is a primary contact residue for the T cell receptor. Our results show that this type of analysis offers a suitable tool for molecular mapping of helper T cell epitopes and thus provides valuable data for subunit vaccine design.</Abstract>
            <ArticleYear>2000</ArticleYear>
            <ArticlePages>190-8</ArticlePages>
            <ArticleTitle>Mapping of a protective helper T cell epitope of human influenza A virus hemagglutinin.</ArticleTitle>
            <Authors>
                <Author>
                    <LastName>Gogolák</LastName>
                    <ForeName>P</ForeName>
                </Author>
                <Author>
                    <LastName>Simon</LastName>
                    <ForeName>A</ForeName>
                </Author>
                <Author>
                    <LastName>Horváth</LastName>
                    <ForeName>A</ForeName>
                </Author>
                <Author>
                    <LastName>Réthi</LastName>
                    <ForeName>B</ForeName>
                </Author>
                <Author>
                    <LastName>Simon</LastName>
                    <ForeName>I</ForeName>
                </Author>
                <Author>
                    <LastName>Berkics</LastName>
                    <ForeName>K</ForeName>
                </Author>
                <Author>
                    <LastName>Rajnavölgyi</LastName>
                    <ForeName>E</ForeName>
                </Author>
                <Author>
                    <LastName>Tóth</LastName>
                    <ForeName>G K</ForeName>
                </Author>
            </Authors>
            <ArticleChemicalList>Epitopes;Hemagglutinin Glycoproteins, Influenza Virus;Histocompatibility Antigens Class II;I-E-antigen;Interleukin-2;Peptide Fragments;Receptors, Antigen, T-Cell;Alanine</ArticleChemicalList>
            <ArticleMeshHeadingsList>Alanine(genetics); Computer Simulation; Epitope Mapping; Epitopes; Hemagglutinin Glycoproteins, Influenza Virus(genetics; immunology); Histocompatibility Antigens Class II(chemistry; immunology); Influenza A virus(genetics; immunology); Interleukin-2(biosynthesis); Lymphocyte Activation; Mutagenesis, Site-Directed; Peptide Fragments(genetics; immunology); Protein Binding; Receptors, Antigen, T-Cell; T-Lymphocytes, Helper-Inducer(immunology)</ArticleMeshHeadingsList>
            <Journal>
                <Volume>270</Volume>
                <Issue>1</Issue>
                <Title>Biochemical and biophysical research communications</Title>
                <Issn>1090-2104</Issn>
                <MedlineTa>Biochem Biophys Res Commun</MedlineTa>
            </Journal>
        </Article>
        <Epitopes>
            <Epitope>
                <EpitopeStructure>
                    <FragmentOfANaturalSequenceMolecule>
                        <ChemicalType>Peptide from protein</ChemicalType>
                        <LinearSequence>VTGLRNIPSI</LinearSequence>
                        <StartingPosition>332</StartingPosition>
                        <EndingPosition>341</EndingPosition>
                        <SourceMolecule>
                            <IedbAccession>SRC133</IedbAccession>
                        </SourceMolecule>
                        <SourceOrganismId>211044</SourceOrganismId>
                    </FragmentOfANaturalSequenceMolecule>
                </EpitopeStructure>
                <LocationOfData>p190, Abstract, Table 1</LocationOfData>
                <EpitopeId>71333</EpitopeId>
                <ReferenceStartingPosition>317</ReferenceStartingPosition>
                <ReferenceEndingPosition>326</ReferenceEndingPosition>
                <EpitopeEvidenceCode>Not determined</EpitopeEvidenceCode>
                <EpitopeStructureDefines>Exact Epitope</EpitopeStructureDefines>
                <EpitopeComments>Deduced minimal epitope derived from multiple truncation analysis. The Swiss Prot given is for the PR8 strain of influenza A virus, but the epitope sequence is identical in many Influenza A viruses of the H1N1 subtype.</EpitopeComments>
                <Assays>
                    <TCell>
                        <LocationOfData>Figures 2B and 2D</LocationOfData>
                        <TCellId>11394</TCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>10090</OrganismId>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Administration in vivo</InVivoProcessType>
                                <ImmunogenObject>
                                    <EpitopeRelation>Fragment of Source Antigen</EpitopeRelation>
                                    <Object>
                                        <FragmentOfANaturalSequenceMolecule>
                                            <ChemicalType>Peptide from protein</ChemicalType>
                                            <LinearSequence>VTGLRNIPSIQSR</LinearSequence>
                                            <StartingPosition>332</StartingPosition>
                                            <EndingPosition>344</EndingPosition>
                                            <SourceMolecule>
                                                <IedbAccession>SRC133</IedbAccession>
                                            </SourceMolecule>
                                            <SourceOrganismId>211044</SourceOrganismId>
                                        </FragmentOfANaturalSequenceMolecule>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenReferenceName>peptide 317-329</ImmunogenReferenceName>
                                <ImmunogenEvidenceCode>Exact match to reference information</ImmunogenEvidenceCode>
                            </FirstInVivoProcess>
                            <SecondInVivoProcess>
                                <InVivoProcessType>Administration in vivo</InVivoProcessType>
                                <ImmunogenObject>
                                    <EpitopeRelation>Source Organism</EpitopeRelation>
                                    <Object>
                                        <Organism>
                                            <SubType>Organism</SubType>
                                            <SourceOrganismId>211044</SourceOrganismId>
                                        </Organism>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenEvidenceCode>Not determined</ImmunogenEvidenceCode>
                            </SecondInVivoProcess>
                            <InVitroAdministration>
                                <ProcessType>Restimulation in vitro</ProcessType>
                            </InVitroAdministration>
                            <ImmunizationComments>BALB/c mice were immunized with the 317-329 peptide and subsequently infected with the A/PR/8/34 influenza A virus. No details on the derivation of the T cell hybridoma are provided.</ImmunizationComments>
                        </Immunization>
                        <EffectorCells>
                            <CellType>T cell</CellType>
                            <CellCultureConditions>Cell Line / Clone (Hybridoma)</CellCultureConditions>
                        </EffectorCells>
                        <AntigenPresentingCells>
                            <CellTissueType>Lymphoid</CellTissueType>
                            <CellType>B cell</CellType>
                            <CellCultureConditions>Cell Line / Clone</CellCultureConditions>
                            <SourceOrganismId>10090</SourceOrganismId>
                        </AntigenPresentingCells>
                        <MhcAllele>
                            <MhcAlleleId>116</MhcAlleleId>
                            <MhcEvidenceCode>MHC binding assay</MhcEvidenceCode>
                        </MhcAllele>
                        <Antigen>
                            <AntigenObject>
                                <EpitopeRelation>Epitope</EpitopeRelation>
                                <Object>
                                    <FragmentOfANaturalSequenceMolecule>
                                        <ChemicalType>Peptide from protein</ChemicalType>
                                        <LinearSequence>VTGLRNIPSI</LinearSequence>
                                        <StartingPosition>332</StartingPosition>
                                        <EndingPosition>341</EndingPosition>
                                        <SourceMolecule>
                                            <IedbAccession>SRC133</IedbAccession>
                                        </SourceMolecule>
                                        <SourceOrganismId>211044</SourceOrganismId>
                                    </FragmentOfANaturalSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Exact match to reference information</AntigenEvidenceCode>
                        </Antigen>
                        <AssayInformation>
                            <AssayTypeId>62</AssayTypeId>
                            <QualitativeMeasurement>Positive</QualitativeMeasurement>
                            <AssayComments>All other peptides containing the minimal epitope  (317-329) also induced secretion of IL-2. The peptide 317-325 gave a negative result in IL-2 assay, suggesting that peptide 317-326 was the minimal epitope.</AssayComments>
                        </AssayInformation>
                    </TCell>
                </Assays>
                <Assays>
                    <MhcBinding>
                        <LocationOfData>Figures 1A and 1C</LocationOfData>
                        <MhcBindingId>11399</MhcBindingId>
                        <AssayInformation>
                            <AssayTypeId>185</AssayTypeId>
                            <QualitativeMeasurement>Positive</QualitativeMeasurement>
                        </AssayInformation>
                        <MhcAlleleId>116</MhcAlleleId>
                    </MhcBinding>
                </Assays>
            </Epitope>
        </Epitopes>
    </Reference>
</References>

